Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 42

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
.4 million, as there were no manufacturing batches of INT230-6 in 2025.

General and administrative expenses during the three months ended June 30, 2025 decreased $0.3 million or 23%, compared to the three months ended June 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.1 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  

•Insurance expense decreased $0.1 million due to the favorable directors and officers insurance renewal terms obtained in June 2024 compared to the prior policy year. 

•Legal and other expenses decreased as a result of cost saving from the integration of new systems in the administrative areas.   

Interest income in 2025 and 2024 related to interest earned on cash and investment balances.  

Six Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2024

Research and development expenses during the six months ended June 30, 2025 decreased $2.6 million or 42%, compared to the six months ended June 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.2 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  In addition, stock-based compensation was $0.4 million lower during the current year period.

•Clinical trial expenses decreased $1.4 million primarily due to lower INVINCIBLE-3 Study costs.  In March 2025, we paused new site activations and patient enrollments in the INVINCIBLE-3 Study, due to funding constraints. Prior to this pause, the trial had enrolled 23 patients.  We will continue to treat all patients enrolled in this study in cooperation with our third-party contract research organizations during this pause, and once sufficient funding is obtained, we plan to restart site activations and patient enrollment.    

•Contract manufacturing costs declined by $0.6 million, as there were no manufacturing batches of INT230-6 in 2025.

General and administrative expenses during the six months ended June 30, 2025 decreased $1.1 million or 31%, compared to the six months ended June 30, 2024, and were primarily due to the